IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer Subtype

IMV Inc IMV announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL).
Related: IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity
8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy;
Of these six evaluable patients, three showed confirmed complete responses, one was assessed with a stable disease as the best response, and two were assessed with progressive disease as the best response.
Two patients with a poor level of baseline functionality (ECOG ≥ 2) failed to stay on the study through to the first scan and, therefore, could not be evaluated.
Price Action: IMV shares are down 15.15% at $1.68 on the last check Monday.